From: Is immunotherapy in the future of therapeutic management of sarcomas?
NCI trial number | Drug | Type of sarcoma | Study design | Phase | Status |
---|---|---|---|---|---|
NCT01803152 | Dendritic Cells Vaccine | Metastatic sarcomas | The patient's dendritic cells used for the vaccine are loaded with tumor lysate. There are three intended dose levels of DC cells per treatment. The vaccine is somministred with topical imiquimod (an immune response modifier), with or without the inhibition of MDSC by gemcitabine pre-treatment | I | Active, not recruiting |
NCT01241162 | Dendritic cell vaccine with adjuvant | Ewings sarcoma, Osteogenic sarcoma, Rhabdomyo sarcoma, Synovial Sarcoma, Neuroblastoma | The dendritic cells used for the vaccine production, was pulsed with overlapping peptides mixes derived from full-length NY-ESO-1, MAGE-A1, and MAGE-A3. The administration of DC vaccine is preceded by decitabine as a demethylating chemotherapy | I | Completed |
NCT00027911 | NY-ESO-1 peptide vaccine + Sargramostim | Soft tissue sarcoma | Patients receive NY-ESO-1 peptide vaccine and receive sargramostim (GM-CS), recombinant granulocyte macrophage colony-stimulating factor, before every vaccination | I | Terminated |
NCT04433221 | Multiple CAR-T cells and sarcoma vaccines | Stage III, IV sarcoma patients or recurrent sarcoma patients; | This trial combines CAR T cells with low dose chemotherapy and followed by maintenance sarcoma vaccines. Chemotherapy, as doxorubicin, is used for the purpose of modulating surface PD-L1 level and enhance immunotherapy effects | I/II | Recruiting |
NCT01258868 | Tumor cell vaccine + ISCOMATRIX Adjuvant | Thoracic sarcomas,mesolthelioma, Esophageal cancer, lung cancer | Patients are vaccinated with autologous tumor cells exposed ex vivo to decitabine,a hypomethylating agent and radiation. Vaccine is administered in conjunction with ISCOMATRIX adjuvant, that induces both humoral and cellular immune responses and with oral celecoxib, an anti-inflammatory | I | Terminated |
NCT00020267 | MAGE-12 peptide vaccine | Soft tissue sarcoma, ovarian sarcoma, melanoma, Colon, lung, breast cancer | Patients received MAGE-12 peptide vaccine emulsified in Montanide ISA-51 adjuvant subcutaneously (SC) weekly for 4 doses (arm A) or once every 3 weeks for 4 doses (arm B). Patients with PD could receive IL-2, with the purpose of increasing the immune response | I | Completed |
NCT04166006 | Dendritic cell vaccine + Interleukin-2 | Soft tissue sarcoma, Neuroendocrine tumors, rare cancer | Patients inject with autologous DC vaccine, that it is followed by subcutaneous injection daily of IL-2, as adjuvant to increase the efficacy of vaccine | II | Recruiting |
NCT01141491 | Trivalent ganglioside vaccine + OPT-821 | Sarcoma | Patients received the vaccine combined with OPT-821, an immune system stimulant (arm A) or the immune system stimulant alone (arm B). The trivalent vaccine should stimulate the immune system to recognize GM2, GD2 and GD3 that are present primarily on sarcoma cells | II | Completed |
NCT00001566 | Dendritic cells + indinavir sulfate | Pediatric ES Rhabdomyosarcoma | Peptide-pulsed antigen presenting cell (APC) vaccine is injected into patients. Following chemotherapy, infusion of harvested T cells followed by infusion of peptide-pulsed APC vaccinations. IL-2 is administered on the same day as T cell /peptide-pulsed infusions | II | Completed |
NCT01341496 | Tumor cell vaccines + ISCOMATRIX | Sarcoma, melanoma, epithelial Malignancies | The autologous tumor cell vaccine is administered with ISCOMATRIX adjuvant in combination with metronomic oral cyclophosphamide and celecoxib in patients undergoing thoracic metastasectomy | I | Terminated |
NCT03357315 | Mix vaccine | Metastatic sarcomas | Patients received mix vaccine (experimental group) or not received treatments (control group). The aim of the study is to evaluate safety and efficacy of mix vaccine on small metastases of sarcoma | I/II | Completed |